If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
A potential issue that arises through the use of NMR is low mass sensitivity, however this can be corrected for by employing microcoils that assist in distinguishing molecules of differing masses. This is necessary since the signal-to-noise ratio of sample sizes in the microliter to nanoliter range is dramatically reduced compared to bench-scale sample sizes, and microcoils have been shown to resolve this issue. Mass spectrometry (MS) and high-performance liquid chromatography (HPLC) have also been used to overcome this challenge. Although MS is an attractive analytical technique for distinguishing the products of reactions accomplished through DMF, it poses its own weaknesses. Matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) MS have recently been paired with analyzing microfluidic chemical reactions. However, crystallization and dilution associated with these methods often leads to unfavorable side effects, such as sample loss and side reactions occurring. The use of MS in DMF is discussed in more detail in a later section.
== Estimation methods == The basic reproduction number can be estimated through examining detailed transmission chains or through genomic sequencing. However, it is most frequently calculated using epidemiological models. During an epidemic, typically the number of diagnosed infections
=== Conservation === The Grhl gene family is tightly conserved between species across an estimated millions of years of evolution, also maintaining the binding site (AACCGGTT) on the target genes of Grhl. While the presence of the Grhl genes varies between species, the functions regulated remain largely analogous. The reason for the presence of multiple Grhl orthologues would likely be due to speciation and the evolution of species from a common ancestor over time. Due to many animals possessing Grhl genes, there are many possible animal models available for research on the Grhl family. At present, the most characterized are the models of Drosophila, mouse and zebrafish. Interestingly, Grh was also identified in fungi, which lack epidermal tissue and instead utilize a cell wall. This gives evidence that the formation of physical barriers across all, or a large variety of, species may have had an evolutionary ancestor that initially developed barrier formation as a result of the presence of a Grhl gene.
==== Liquid crystal microcapsules ==== Fabrication of liquid crystals has been a point of intrigue for over 5 decades for their anisotropic properties. Microfluidic devices can be used for the synthesis of confined cholesteric liquid crystals through layering of multiple shell-like layers consisting of varying oil-in-water and water-in-oil emulsions. The construction of encapsulated liquid crystals through microfluidic flow of liquid crystal droplets in an immiscible oil allows for monodispersed emulsion layer thickness and composition previously unseen before the advent of microfluidic techniques. The advent of liquid crystal technology has led to advancements in optical displays used both in research and consumer branded products, but more recent discoveries have opened the door to the combination of photon combination and upconversion as well as optical sensors for biological analytes.
==== Ingestion ==== While null in comparison to the concentrations found in indoor air, benzene, toluene, and methyl tert-butyl ether (MTBE) were found in samples of human milk and increase the concentrations of VOCs that we are exposed to throughout the day. A study notes the difference between VOCs in alveolar breath and inspired air suggesting that VOCs are ingested, metabolized, and excreted via the extra-pulmonary pathway. VOCs are also ingested by drinking water in varying concentrations. Some VOC concentrations were over the EPA's National Primary Drinking Water Regulations and China's National Drinking Water Standards set by the Ministry of Ecology and Environment.
Sources: en.wikipedia.org
It is noteworthy that the genetic code for all organisms is basically the same, so that all living beings use the same 'genetic language'. In general, the introduction of new functional unnatural amino acids into proteins of living cells breaks the universality of the genetic language, which ideally leads to alternative life forms. Proteins are produced thanks to the translational system molecules, which decode the RNA messages into a string of amino acids. The translation of genetic information contained in messenger RNA (mRNA) into a protein is catalysed by ribosomes. Transfer RNAs (tRNA) are used as keys to decode the mRNA into its encoded polypeptide. The tRNA recognizes a specific three nucleotide codon in the mRNA with a complementary sequence called the anticodon on one of its loops. Each three-nucleotide codon is translated into one of twenty naturally occurring amino acids. There is at least one tRNA for any codon, and sometimes multiple codons code for the same amino acid. Many tRNAs are compatible with several codons. An enzyme called an aminoacyl tRNA synthetase covalently attaches the amino acid to the appropriate tRNA. Most cells have a different synthetase for each amino acid (20 or more synthetases). On the other hand, some bacteria have fewer than 20 aminoacyl tRNA synthetases, and introduce the "missing" amino acid(s) by modification of a structurally related amino acid by an aminotransferase enzyme.
{\displaystyle {\begin{aligned}F_{n}(h)&=\int _{h}^{\infty }(s-h)^{n}\phi ^{*}(s)ds\\n&=\eta A_{n}F_{0}(h)\\A_{a}&=\pi \eta AR\sigma F_{1}(h)\\P&={\frac {4}{3}}\eta AE_{r}{\sqrt {R}}\sigma ^{\frac {3}{2}}F_{\frac {3}{2}}(h)\end{aligned}}}
Some of the multiple activities of thymosin β4 unrelated to actin may be mediated by a tetrapeptide enzymically cleaved from its N-terminus, N-acetyl-ser-asp-lys-pro, brand names Seraspenide or Goralatide, best known as an inhibitor of the proliferation of haematopoietic (blood-cell precursor) stem cells of bone marrow.
5-MeO-DMT Bufotenine crack cocaine dimethyltryptamine (DMT) DiPT methamphetamine Methaqualone phencyclidine (PCP) synthetic cannabinoids (see also: synthetic cannabis) many others, including some prescription drugs
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.